CA2625600A1 - Proteines hybrides de transferrine modifiees par des peptides natriuretiques - Google Patents

Proteines hybrides de transferrine modifiees par des peptides natriuretiques Download PDF

Info

Publication number
CA2625600A1
CA2625600A1 CA002625600A CA2625600A CA2625600A1 CA 2625600 A1 CA2625600 A1 CA 2625600A1 CA 002625600 A CA002625600 A CA 002625600A CA 2625600 A CA2625600 A CA 2625600A CA 2625600 A1 CA2625600 A1 CA 2625600A1
Authority
CA
Canada
Prior art keywords
fusion protein
transferrin
protein
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002625600A
Other languages
English (en)
Inventor
Homayoun Sadeghi
Andrew J. Turner
Christopher P. Prior
David J. Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2625600A1 publication Critical patent/CA2625600A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644Transferrin, e.g. a lactoferrin or ovotransferrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002625600A 2005-10-14 2006-10-16 Proteines hybrides de transferrine modifiees par des peptides natriuretiques Abandoned CA2625600A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72619805P 2005-10-14 2005-10-14
US60/726,198 2005-10-14
PCT/US2006/040207 WO2007047504A2 (fr) 2005-10-14 2006-10-16 Proteines hybrides de transferrine modifiees par des peptides natriuretiques

Publications (1)

Publication Number Publication Date
CA2625600A1 true CA2625600A1 (fr) 2007-04-26

Family

ID=37963135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002625600A Abandoned CA2625600A1 (fr) 2005-10-14 2006-10-16 Proteines hybrides de transferrine modifiees par des peptides natriuretiques

Country Status (4)

Country Link
EP (1) EP1951277A2 (fr)
JP (1) JP2009511060A (fr)
CA (1) CA2625600A1 (fr)
WO (1) WO2007047504A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689492A1 (fr) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Proteines de fusion natriuretiques
WO2009097017A2 (fr) 2007-09-18 2009-08-06 The Jackson Laboratory Modifications d'anticorps et de protéines de fusion fc présentant une persistance accrue ou une stabilité pharmacocinétique in vivo et leurs procédés d'utilisation
WO2011038066A2 (fr) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Nouveaux agonistes des npr-b
UY32902A (es) 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
US9018168B2 (en) 2010-08-12 2015-04-28 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
KR102188544B1 (ko) 2010-11-30 2020-12-08 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
WO2012115772A2 (fr) 2011-02-25 2012-08-30 Medtronic, Inc. Thérapie pour néphropathie et/ou insuffisance cardiaque
EP2750697A4 (fr) 2011-09-02 2015-03-25 Medtronic Inc Compositions de peptides natriurétiques chimériques et procédés de préparation
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
DK2968470T3 (da) 2013-03-12 2021-02-01 Massachusetts Gen Hospital Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme
MY193211A (en) 2013-03-15 2022-09-26 Bayer Healthcare Llc Gla domains as targeting agents
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
JP6665104B2 (ja) 2014-04-10 2020-03-13 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 配合培地粉末製剤および細胞培養用液体培地の調製方法
WO2022057821A1 (fr) * 2020-09-16 2022-03-24 Suzhou Neologics Bioscience Co. , Ltd. Anticorps anti-pd-l1, protéines de fusion et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440311A1 (fr) * 1985-06-20 1991-08-07 Fujisawa Pharmaceutical Co., Ltd. Procédé de production d'un polypeptide humain alpha atrionatriuretique
ATE330967T1 (de) * 1999-07-02 2006-07-15 Genentech Inc An her2 bindende peptidverbindungen
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins

Also Published As

Publication number Publication date
EP1951277A2 (fr) 2008-08-06
JP2009511060A (ja) 2009-03-19
WO2007047504A2 (fr) 2007-04-26
WO2007047504A3 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
CA2625600A1 (fr) Proteines hybrides de transferrine modifiees par des peptides natriuretiques
US20060205037A1 (en) Modified transferrin fusion proteins
CA2599723A1 (fr) Proteines hybrides modifiees de transferrine
US20070275871A1 (en) Epo Mimetic Peptides and Fusion Proteins
DK1611093T3 (en) Fusion proteins with modified transferrin
KR101193722B1 (ko) 엑센딘 융합 단백질
JP4949838B2 (ja) 新規glp−1誘導体
JP6585197B2 (ja) グルカゴン及びglp−1共アゴニスト化合物
AU2009202932B2 (en) Modified transferrin fusion proteins
ES2535358T3 (es) Bibliotecas de proteínas de fusión de transferrina
US20070060512A1 (en) Dipeptidyl-peptidase protected protein
JP2010500031A (ja) アルブミン−インスリン融合タンパク質
CA2575756A1 (fr) Polytherapie basee sur l'utilisation de proteines hybrides de transferrine contenant du glp-1
WO2007112940A2 (fr) Séquence d'acides aminés dérivée de l'albumine, son utilisation pour augmenter la demi-vie de protéines thérapeutiques et d'autres composés et entités thérapeutiques, et produits de recombinaison qui la comprennent
WO2004019872A2 (fr) Delivrance orale de proteines hybrides modifiees de la transferrine
WO2006049983A2 (fr) Proteines de fusion de transferine modifiees par le peptide yy
WO2008021412A2 (fr) PROTÉINES DE FUSION DE L'INTERFÉRON β ET DE LA TRANSFERRINE
Wang Proinsulin-transferrin recombinant fusion protein: Mechanism of activation and potential application in diabetes treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead